Get informed when a big investor buys or sells
+ FollowOvervalued by 43.7% based on the discounted cash flow analysis.
Loading insider trades…
Loading congress trades…
| Market cap | $4.95 Billion |
|---|---|
| Enterprise Value | $34.20 Billion |
| Annual dividend | $0.06 |
| Dividend yield | 1.73% |
| Earnings per Share | $1.26 |
| Beta | 0.44 |
| Outstanding Shares | 2,639,554,000 |
| P/E Ratio | 16.94 |
|---|---|
| PEG | 111.57 |
| Price to Sales | 0.08 |
| Price to Book Ratio | 0.08 |
| Enterprise Value to Revenue | 0.55 |
| Enterprise Value to EBIT | 6.81 |
| Enterprise Value to Net Income | 6 |
| Total Debt to Enterprise | 1.24 |
| Debt to Equity | 0.85 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a comprehensive healthcare enterprise, operating across Mainland China and international markets. Its principal activities include the research, development, production, and commercializ...